Edimer Pharmaceuticals is a company.
Edimer Pharmaceuticals has raised $18.0M across 1 funding round.
Key people at Edimer Pharmaceuticals.
Edimer Pharmaceuticals has raised $18.0M in total across 1 funding round.
Edimer Pharmaceuticals is a biotechnology company founded in 2009 and headquartered in Cambridge, Massachusetts, focused on developing therapies for rare genetic diseases, particularly X-linked Hypohidrotic Ectodermal Dysplasia (XLHED).[1][2][3] The company targeted EDI200, a treatment aimed at improving health and quality of life for patients with XLHED—a rare orphan disease causing symptoms like absent sweat glands, poor temperature regulation, respiratory issues, and malformations of hair and teeth—serving affected families with no existing curative options.[2][4][5] It raised $18 million in Series B funding in 2013 from investors including Sanofi-Genzyme BioVentures, but search results indicate limited recent activity, with profiles describing it in past tense as "was a biotechnology company."[2][3]
Edimer Pharmaceuticals emerged in 2009 amid growing interest in orphan drugs for rare genetic disorders, established as a privately held biotech firm in Cambridge, MA.[1][2][3] Key figures included Neil (likely CEO or executive), a pharmaceutical veteran with over 20 years at Biogen, Vertex, and others, specializing in regulatory affairs, development, and launches of biopharmaceuticals like enzyme replacement therapies; and Dr. Cary P. (or similar), interim CEO elsewhere and Third Rock Ventures partner, with expertise in business development and board roles at Edimer and peers like Eleven Biotherapeutics.[4] The idea stemmed from addressing unmet needs in XLHED, leading to early traction via EDI200 development and orphan drug designations, plus a pivotal $18M Series B round in July 2013.[2][4][6]
Edimer rode the early 2010s wave of orphan drug innovation, where market forces like FDA incentives (7-year exclusivity, tax credits) and rising venture interest in rare diseases fueled biotech startups targeting underserved genetics.[3][6] Timing was ideal post-genomics era, enabling precise therapies for conditions like XLHED amid advances in protein replacement and gene modulation. It contributed to Cambridge's biotech cluster ecosystem, influencing rare disease R&D by demonstrating viability for single-indication firms and attracting investors to high-unmet-need areas, though its footprint appears modest compared to scaled peers.[1][2]
Edimer's trajectory highlights biotech risks in rare diseases: strong early momentum with EDI200 and funding, but profiles suggest dormancy or shutdown post-2013, common in clinical-stage ventures facing trial setbacks or funding gaps.[3] Next steps likely hinge on acquisition (e.g., by Sanofi-like players) or revival via new orphan incentives; trends like gene editing (CRISPR) and AI-driven drug discovery could reshape XLHED treatments, potentially eclipsing EDI200. Its legacy endures in validating niche orphan plays, underscoring how focused biotechs like Edimer pave paths for ecosystem-wide advances in genetic medicine.[1][2][6]
Key people at Edimer Pharmaceuticals.
Edimer Pharmaceuticals has raised $18.0M in total across 1 funding round.
Edimer Pharmaceuticals's investors include Mott Family Capital, Omega Funds.
Edimer Pharmaceuticals has raised $18.0M across 1 funding round. Most recently, it raised $18.0M Series B in July 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2013 | $18.0M Series B | Mott Family Capital, Omega Funds |
